-
公开(公告)号：US07595314B2
公开(公告)日：2009-09-29
申请号：US12177386
申请日：2008-07-22
申请人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号： A61K31/5377 , A61K31/496 , A61K31/55 , C07D413/12
CPC分类号： C07D295/192 , A61K31/495 , A61K31/496 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D307/14 , C07D309/14
摘要： A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译： 式的化合物，其中取代基如治疗精神病，疼痛，记忆和学习中的神经变性功能障碍，精神分裂症，痴呆和其他认知过程受损的其他疾病（如注意力缺陷障碍或阿尔茨海默氏病）的描述中所述。
-
公开(公告)号：US20090192136A1
公开(公告)日：2009-07-30
申请号：US12177386
申请日：2008-07-22
申请人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号： A61K31/496 , C07D413/10 , C07D241/04 , A61K31/55 , A61K31/5377 , A61P25/00 , A61K31/495 , C07D405/12
CPC分类号： C07D295/192 , A61K31/495 , A61K31/496 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D307/14 , C07D309/14
摘要： A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译： 式的化合物，其中取代基如治疗精神病，疼痛，记忆和学习中的神经变性功能障碍，精神分裂症，痴呆和其他认知过程受损的其他疾病（如注意力缺陷障碍或阿尔茨海默病）的治疗方法所述。
-
公开(公告)号：US07462617B2
公开(公告)日：2008-12-09
申请号：US10933072
申请日：2004-09-01
申请人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号： A61K31/53 , A61K31/496 , C07D295/192 , C07D409/12 , C07D251/22 , C07D251/24 , A61K31/495
CPC分类号： C07D295/16 , A61K31/495 , A61K31/496 , C07D213/56 , C07D213/69 , C07D213/74 , C07D233/64 , C07D239/26 , C07D239/42 , C07D241/12 , C07D251/42 , C07D251/48 , C07D257/04 , C07D263/32 , C07D277/30 , C07D295/185 , C07D309/04 , C07D309/20 , C07D333/24 , C07D409/12
摘要： The invention relates to compounds of formula wherein the substituents are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention further relates to methods for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other d 1iseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译： 本发明涉及下式的化合物，其中取代基如说明书中所定义，及其药学上可接受的酸加成盐。 本发明还涉及用于治疗精神病，疼痛，记忆和学习中的神经变性功能障碍，精神分裂症，痴呆和其他认知过程受损的其他疾病的方法，例如注意力缺陷障碍或阿尔茨海默病。
-
公开(公告)号：US07427612B2
公开(公告)日：2008-09-23
申请号：US10933103
申请日：2004-09-02
申请人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人： Daniela Alberati-Giani , Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号： A61K31/55 , A61K31/5377 , A61K31/496 , C07D295/192
CPC分类号： C07D295/192 , A61K31/495 , A61K31/496 , C07D207/08 , C07D207/12 , C07D207/20 , C07D211/42 , C07D231/12 , C07D233/54 , C07D237/20 , C07D249/08 , C07D257/04 , C07D307/14 , C07D309/14
摘要： A compound of formula wherein the substituents are as described in the specification for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译： 式的化合物，其中取代基如治疗精神病，疼痛，记忆和学习中的神经变性功能障碍，精神分裂症，痴呆和其他认知过程受损的其他疾病（如注意力缺陷障碍或阿尔茨海默氏病）的描述中所述。
-
公开(公告)号：US07384945B2
公开(公告)日：2008-06-10
申请号：US11257885
申请日：2005-10-25
IPC分类号： A61K31/497 , A61K31/40 , A01N43/38 , C07D401/00 , C07D211/78 , C07D211/90 , C07D213/81 , C07D209/42 , C07D403/00
CPC分类号： C07D235/12 , C07D209/12 , C07D401/06
摘要： Provided are compounds of the formula I: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
摘要翻译： 提供式I化合物及其药学上可接受的盐，制备所述化合物及其药学上可接受的盐的方法，包含所述化合物的药物组合物及其药学上可接受的盐以及使用所述化合物的方法。 该化合物可用于治疗和/或预防与调节CB1受体相关的疾病。
-
公开(公告)号：US20080119486A1
公开(公告)日：2008-05-22
申请号：US11931379
申请日：2007-10-31
申请人： Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
发明人： Synese Jolidon , Robert Narquizian , Matthias Heinrich Nettekoven , Roger David Norcross , Emmanuel Pinard , Henri Stalder
IPC分类号： A61K31/495 , C07D295/03 , A61P25/18 , A61P25/28 , A61P25/00
CPC分类号： C07D239/42 , C07D213/85 , C07D241/20 , C07D251/42 , C07D257/04 , C07D263/32 , C07D271/06 , C07D295/192 , C07D309/12
摘要： The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
摘要翻译： 本发明涉及下式的化合物，其中取代基在本文中描述。 该化合物可用于基于甘氨酸摄取抑制剂治疗疾病，例如精神病，疼痛，记忆和学习中的神经变性功能障碍，精神分裂症，痴呆等认知过程受损的其他疾病，如注意力缺陷障碍或阿尔茨海默病 疾病。
-
公开(公告)号：US07250431B2
公开(公告)日：2007-07-31
申请号：US10915199
申请日：2004-08-10
IPC分类号： A61K31/426 , A61K31/427 , C07D277/38
CPC分类号： C07D417/12 , C07D277/42
摘要： Thiazole derivatives of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R5, a and b have the significance given in the specification. The compounds are neuropeptide Y Y5 receptor antagonists which can be used for the treatment of obesity.
摘要翻译： 提供式I的噻唑衍生物以及其药学上可接受的盐和酯，其中R 1至R 5，a和b具有说明书中给出的含义。 该化合物是可用于治疗肥胖症的神经肽Y Y5受体拮抗剂。
-
公开(公告)号：US07229999B2
公开(公告)日：2007-06-12
申请号：US11397743
申请日：2006-04-04
申请人： Paul Hebeisen , Hans Iding , Matthias Heinrich Nettekoven , Ulrike Obst , Stephan Roever , Beat Wirz
发明人： Paul Hebeisen , Hans Iding , Matthias Heinrich Nettekoven , Ulrike Obst , Stephan Roever , Beat Wirz
IPC分类号： A61K31/44 , A51N43/54 , C07D213/22 , C07D213/56 , C07D401/00
CPC分类号： C07D213/64 , C07D213/74 , C07D213/82 , C07D401/12 , C07D413/12 , C07D417/12
摘要： The present invention relates to compounds of the formula wherein X and R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
摘要翻译： 本发明涉及下式的化合物，其中X和R 1至R 8如在说明书和权利要求书中所定义，及其药学上可接受的盐。 该化合物可用于治疗和/或预防与调节CB1受体如肥胖相关的疾病。
-
公开(公告)号：US07205309B2
公开(公告)日：2007-04-17
申请号：US10613782
申请日：2003-07-03
申请人： Patrizio Mattei , Werner Mueller , Werner Neidhart , Matthias Heinrich Nettekoven , Philippe Pflieger
发明人： Patrizio Mattei , Werner Mueller , Werner Neidhart , Matthias Heinrich Nettekoven , Philippe Pflieger
IPC分类号： A61K31/55 , A61K31/54 , A61K31/517 , C07D239/72 , C07D413/00 , C07D417/00 , C07D419/00
CPC分类号： C07D401/12 , C07D239/94 , C07D239/95 , C07D401/14 , C07D403/04 , C07D405/12
摘要： Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3 and A have the significance given in the specification are provided. The compounds can be used for the treatment or prevention of obesity.
摘要翻译： 式I化合物
-
公开(公告)号：US07012073B2
公开(公告)日：2006-03-14
申请号：US10896445
申请日：2004-07-22
申请人： Michael G. Klug , Patrizio Mattei , Werner Mueller , Werner Neidhart , Matthias Heinrich Nettekoven , Philippe Pflieger , Jean-Marc Plancher
发明人： Michael G. Klug , Patrizio Mattei , Werner Mueller , Werner Neidhart , Matthias Heinrich Nettekoven , Philippe Pflieger , Jean-Marc Plancher
IPC分类号： C07D401/04 , C07D401/14 , A61K31/55 , A61K31/4709 , A61P3/04
CPC分类号： C07D401/04 , C04B35/632 , C07D215/42 , C07D401/12 , C07D405/14
摘要： Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3, A1 and A2 have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.
摘要翻译： 式I化合物及其药学上可接受的盐和酯，其中R 1，R 2，R 3，A 1， 具有权利要求1给出的意义的化合物可以以用于治疗或预防关节炎，心血管疾病，糖尿病，肾功能衰竭，饮食失调的药物制剂的形式使用， 肥胖。
-
-
-
-
-
-
-
-
-
搜索结果
52 条记录 (耗时 0.062 秒)
